
Review Article**The relationship of *H.pylori* infection with certain common diseases in the society****Fulya Bayındır Bilman**

İzmir Menemen State Hospital, Department of Medical Microbiology, Turkey

Abstract: *H. pylori* is a gram negative bacterium which settles in the stomach mucosa and causes inflammation and infection. The infection is strongly related to duodenal ulceration, gastric ulceration, and from time to time gastric carcinoma. There are many studies in which the relationship between the infection of this quite old but current bacterium in stomach /duodenum and different extra-intestinal diseases has been investigated. Among the extra-intestinal diseases, the most common are asthma, rosacea, chronic idiopathic urticarial, atopy, coronary heart disease and migraine. In this review, it has been aimed to study the data obtained from the fields in this field, and the results have been assessed.

Key words: *H.pylori*, Astma, Rosacea, Coronary Heart Disease, Migraine

Introduction

H.pylori, a pathogen dating back to very old times in gastrointestinal system, is a gram negative bacterium in spiral structure (1). In the performed autopsy studies, it has been reported that *H.pylori* genome was detected even in people of thousands of years ago (2). Apart from the known classical infection, studies in different fields have been conducted in relation to *H.pylori* in the last two decades.

The foremost among them, the studies in which the relationship with asthma is investigated attract attention (3-5). In a meta analysis study cited by Wang et al. (3) by examining all studies published n 770 subjects 785 control group, they report that they could not come to a conclusion of a statistically significant relationship between *H.pylori* and asthma. In a study conducted by Annagür et al. (4) on a group with asthma attacks (n=37) and on 79 patients including children with stable asthma (n=42), they reported that there is no relationship between *H.pylori* presence and asthma. In addition to these, Blaser et al. (5) drew attention to the fact that the rarity of *H.pylori* in developed countries can be a factor that increases the risk of bronchial asthma with hygiene hypothesis. According to hygiene hypothesis, living in an environment surrounded with natural antigens is necessary for normal immune maturation. Therefore, it can be possible to get protected from asthma and allergic diseases. There are studies that have data to support this hypothesis (6.7). Chen et al. (6) determined that there is a statistically significant reverse relationship between *H.pylori* antigen positivity and asthma incidence in children under the age of 5. Again, a similar finding was reported by Reibman et al. (7). According to these findings, 318 adult asthma cases and 208 control cases were studied. The findings of the study indicated that the people colonized by CagA positive *H.pylori* were protected from asthma and it caused delay at the age of disease onset. Considering the data of a meta analysis obtained in recent years in this field, *H.pylori* positivity was reported by Zhou et

al. (8) to be present in asthma cases at much less levels when 14 articles were evaluated including 28.283 cases.

According to a study in which a hypothesis that *H.pylori* infection can be protective from atopy as well as in asthma cases was investigated, the risk of atopy development in the presence of *H.pylori* infection was found to decrease by 18% in a meta analysis report covering 21.348 cases (9).

Rosacea disease is a chronic dermatologic disease characterized by erythema, telangiectasia and pustular change. There are findings that some microbial agents can trigger this disease. Especially the findings on *Demodex folliculorum* and *H.pylori* verify these opinions (10-12). In a study carried out recently (12), whether there is a relationship or not between *H.pylori* and rosacea clinic has been investigated in the patients diagnosed with small intestinal bacterial overgrowth (SIBO) detected with *H.pylori*. In the course of this study, skin lesions displayed improvement by 97.2% and pronounced regression within 10 weeks (12) after implementing clarithromycin-containing sequential therapy. In a similar study including similar findings, it is suggested that a *H.pylori* analysis should absolutely be made in rosacea patients and positive cases will greatly benefit from eradication therapy for especially papulopustular subtype (13). Ocular involvement is encountered in more than half of all rosacea cases (14). It was reported by Dakovic et al. (14) that a pronounced improvement was detected both in skin lesions and in ocular findings within 6 weeks after the *H.pylori* eradication treatment n 7 rosacea cases having positive *H.pylori* antigen test and also displaying ocular involvement. Jorgensen et al. included 928 rosacea patients and 1527 controls in the meta analysis report they published by examining 42 articles (15). The researchers emphasized that they detected a weak relationship with no statistical significance between rosacea clinic and treatment and *H.pylori* in contrast to previous studies. Yet, the pathological link between the two conditions

is stated to be related to other factors whose existence is unknown.

There are many studies investigating the clinic link between bacterial infections and peripheral vascular disease (PVD) and the roles in pathogenesis (16). Gout microbiota, periodontal bacteria, *Chlamydia pneumoniae* and *H.pylori* are important pathogens that come to mind in PVD pathogenesis. Although *H.pylori* is an infection agent known with direct cytotoxic and proinflammatory effects for upper digestive tract, it also affects brain-gut axis indirectly (17). Depending on *H.pylori* infection, the host's neuroendocrine-immunological reaction followed with changes in cognitive functions and immunological response differences are also observed (18). In a study including quite serious findings, Kowalski (19) detected *H.pylori* DNA in atheromatous plaque material in coronary vessels, on the other hand, emphasized a reduction in restenosis in coronary vessels after *H.pylori* eradication. In this study, the role of *H.pylori* infection in the inflammatory process has been discussed with several data in the progression of coronary artery disease (CAD). For example, *H.pylori* seropositivity rate was found in 69.79% of CAD group, while a statistically significant difference was found in the control group (40.62%). In addition, CagA IgG level was similarly found to be significantly high in CAD group. The data on the contraction of artery lumen was found at a more serious level in CagA positive *H.pylori* cases (19). In other studies, after the eradication treatment, the decrease in proinflammatory cytokine release and eradication of chronic inflammation have been interpreted as the indicators that explain the reduction in the risk of re-occurrence of CAD (20,21).

Jha et al., having made a study about the important roles of such factors as *C.pneumoniae*, *H.pylori*, Cytomegalovirus in CAD pathogenesis, put forward that the traces belonging to these factors can be used as markers in the target audience (22). In this study, IgA and IgG levels of pathogen microorganisms and an important inflammatory marker C reactive protein levels in 192 CAD cases have been compared to the control group. Statistically significant results have been obtained in all of them. These data have assisted to enlighten the role of these microorganisms in CAD pathogenesis.

One of the extragastric manifestations of *H.pylori* infection is Diabetes Mellitus (DM). Even though DM cases do not have dyspeptic symptoms, *H.pylori* infection prevalence has been reported to be higher than the controls and to have a positive relationship with insulin resistance (IR) (23). Especially in type 2 DM patients, there are scientific papers informing that more susceptibility is seen towards *H.pylori* infections (24). Because DM has multifactorial pathogenesis, it is difficult to exactly determine the role of *H.pylori* in pathogenesis. However, a large number of studies, which inform that a significant difference is not seen in terms of glycemic control after the *H.pylori* eradication treatment, are presented in meta analyses (25-27). In addition, neuropathy incidence has been detected to be higher in diabetics with *H.pylori* infection. Vafaeianesh et al. reported that the eradication rate of *H.pylori*

with combination treatments is lower in patients with type 2 diabetes than non-diabetic ones (26). According to some reports, relationship between *H.pylori* and migraine disease has been reported (28). There are some data that recurrent headache can develop secondary to *H.pylori* infection and this situation depends on systemic vasospastic effects caused by pro-inflammatory substances released from infected gastric mucosa (29,30). In the meta analysis of the studies made in 2000-2013 on migraine patients, Su et al. found out that the prevalence of *H.pylori* infection in 903 migraine cases was 39.31%, and was significantly higher than controls (28). In a study in which headache severity level was assessed according to Headache Impact Test (HIT6) questionnaire, Ansari et al. detected a statistically significant correlation between IgG level against *H.pylori* and frequency and severity of migraine attacks. considering the consequences of eradication treatment, the treatment is reported to be promising in reducing the severity of migraine and the number of attacks.

References

1. Amin Talebi Bezmin Abadi and Johannes Kusters. *Helicobacter pylori - A Worldwide Perspective* 2014. Book, March 2014. Publisher: Bentham ebooks, Editor: György Miklós Buzás, ISBN: 978-1-60805-738-2.
2. <http://www.nature.com/news/famous-ancient-iceman-had-familial-stomach-infection-1.19127> Access date: June 10, 2017.
3. Wang Y, Bi Y, Zhang L, Wang C. Is *Helicobacter Pylori* Infection Associated with Asthma Risk? A Meta-Analysis Based on 770 Cases and 785 Controls. *Int J Med Sci* 2012; 9(7): 603-610. doi:10.7150/ijms.4970.
4. Annagur A, Kendirli SG, Yilmaz M, Altintas DU, Inal A. Is there any relationship between asthma and atypical bacterial infections; *Chlamydia pneumoniae*, *Mycoplasma pneumoniae* and *Helicobacter pylori*. *J Trop Pediatr* 2007; 53(5): 313-8 doi:10.1093/tropej/fmm040.
5. Blaser MJ, Chen Y, Reibman J: Does *Helicobacter pylori* protect against asthma and allergy? *Gut* 2008; 57:561–567.
6. Chen Y, Blaser MJ: *Helicobacter pylori* colonization is inversely associated with childhood asthma. *J Infect Dis* 2008;198: 553–560. doi: 10.1086/590158
7. Reibman J, Marmor M, Filner J, Fernandez-Beros M, Rogers L, Perez-Perez GI. et al: Asthma is inversely associated with *Helicobacter pylori* status in an urban population. *PLoS One* 2008;3:e4060. doi/10.1371/journal.pone.0004060.
8. Zhou X, Wu J, Zhang G. Association between *Helicobacter pylori* and asthma: a meta-analysis. *Eur J Gastroenterol Hepatol.* 2013; 25(4): 460-8. doi: 10.1097/MEG.0b013e32835c280a.
9. Taye B, Enquesslassie F, Tsegaye A, Medhin G, Davey G, Venn A. Is *Helicobacter pylori* infection inversely

- associated with atopy? A systematic review and meta-analysis. *Clin Exp Allergy*. 2015; 45(5): 882-90. doi: 10.1111/cea.12404.
10. Agnoletti AF, DE Col E, Parodi A, Schiavetti I, Savarino V, Rebora A, Paolino S, Cozzani E, Drago F. Etiopathogenesis of rosacea: a prospective study with a three-year follow-up. *G Ital Dermatol Venereol*. 2016 Feb 18. [Epub ahead of print]
 11. Tuzun Y, Keskin S, Kote E. The role of *Helicobacter pylori* infection in skin diseases: Facts and controversies. *Clin Dermatol* 2010; 28: 478–482.
 12. Gravina AG, Federico A, Ruocco E, Schiavo A Lo, Masarone M, Tuccillo C, et al. *Helicobacter pylori* infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea. *United European Gastroenterol J*. 2015; 3(1): 17-24. doi: 10.1177/2050640614559262.
 13. Boixeda de Miquel D, Vázquez Romero M, Vázquez Sequeiros E, Foruny Olcina JR, Boixeda de Miquel P, López San Román A, et al. Effect of *Helicobacter pylori* eradication therapy in rosacea patients. *Rev Esp Enferm Dig*. 2006; 98(7):5 01-9.
 14. Daković Z, Vesić S, Vuković J, Milenković S, Janković-Terzić K, Dukić S, et al. Ocular rosacea and treatment of symptomatic *Helicobacter pylori* infection: a case series. *Acta Dermatovenerol Alp Pannonica Adriat*. 2007 6(2): 83-6.
 15. Jørgensen AR, Egeberg A, Gideonsson R, Weinstock LB, Thyssen EP, Thyssen JP. Rosacea is associated with *Helicobacter pylori*: a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol*. 2017; 23. doi: 10.1111/jdv.14352. [Epub ahead of print]
 16. Budzyński J, Wiśniewska J, Ciecierski M, Kędzia A. Association between Bacterial Infection and Peripheral Vascular Disease: A Review. *Int J Angiol*. 2016; 25(1): 3-13. doi: 10.1055/s-0035-1547385.
 17. Budzyński J, Kłopocka M. Brain-gut axis in the pathogenesis of *Helicobacter pylori* infection. *World Journal of Gastroenterology : WJG*. 2014; 20(18): 5212-5225. doi:10.3748/wjg.v20.i18.5212.
 18. Bercik P, Verdú EF, Foster JA, Lu J, Scharringa A, Kean I, Wang L, Blennerhassett P, Collins SM. Role of gut-brain axis in persistent abnormal feeding behavior in mice following eradication of *Helicobacter pylori* infection. *Am J Physiol Regul Integr Comp Physiol*. 2009 Mar; 296(3):R587-94.
 19. Kowalski M. *Helicobacter pylori* (*H. pylori*) infection in coronary artery disease: influence of *H. pylori* eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of *H. pylori* specific DNA in human coronary atherosclerotic plaque. *J Physiol Pharmacol*. 2001; 52(1): 3-31.
 20. Sessa R, Pietro MD, Filardo S, Turriziani O. Infectious burden and atherosclerosis: A clinical issue. *World J Clin Cases*. 2014; 2(7): 240-9. doi: 10.12998/wjcc.v2.i7.240.
 21. Kowalski M, Pawlik M, Konturek JW, Konturek SJ. *Helicobacter pylori* infection in coronary artery disease. *J Physiol Pharmacol*. 2006; 57(3): 101-11.
 22. Jha HC, Prasad J, Mittal A. High immunoglobulin A seropositivity for combined *Chlamydia pneumoniae*, *Helicobacter pylori* infection, and high-sensitivity C-reactive protein in coronary artery disease patients in India can serve as atherosclerotic marker. *Heart Vessels*. 2008; 23(6):390-6. doi: 10.1007/s00380-008-1062-9.
 23. Marietti M, Gasbarrini A, Saracco G, Pellicano R. *Helicobacter pylori* infection and diabetes mellitus: the 2013 state of art. *Panminerva Med*. 2013; 55(3): 277-81.
 24. Zhou X, Zhang C, Wu J, Zhang G. Association between *Helicobacter pylori* infection and diabetes mellitus: a meta-analysis of observational studies. *Diabetes Res Clin Pract*. 2013; 99(2): 200-8. doi: 10.1016/j.diabres.2012.11.012.
 25. Demir M, Gokturk HS, Ozturk NA, Kulaksizoglu M, Serin E, Yilmaz U. *Helicobacter pylori* prevalence in diabetes mellitus patients with dyspeptic symptoms and its relationship to glycemic control and late complications. *Dig Dis Sci*. 2008; 53(10): 2646-9. doi: 10.1007/s10620-007-0185-7.
 26. Vafaeimanesh J, Rajabzadeh R, Ahmadi A, Moshtaghi M, Banikarim S, Hajiebrahimi S, et al. Effect of *Helicobacter pylori* eradication on glycaemia control in patients with type 2 diabetes mellitus and comparison of two therapeutic regimens. *Arab J Gastroenterol*. 2013; 14(2): 55-8. doi: 10.1016/j.ajg.2013.03.002.
 27. Dai YN, Yu WL, Zhu HT, Ding JX, Yu CH, Li YM. Is *Helicobacter pylori* infection associated with glycemic control in diabetics? *World J Gastroenterol*. 2015; 21(17): 5407-16. doi: 10.3748/wjg.v21.i17.5407.
 28. Su J, Zhou XY, Zhang GX. Association between *Helicobacter pylori* infection and migraine: a meta-analysis. *World J Gastroenterol*. 2014; 20(40): 14965-72. doi: 10.3748/wjg.v20.i40.14965.
 29. Ansari B, Basiri K, Meamar R, Chitsaz A, Nematollahi S. Association of *Helicobacter pylori* antibodies and severity of migraine attack. *Iranian Journal of Neurology*. 2015; 14(3): 125-129.
 30. Hosseinzadeh M, Khosravi A, Saki K, Ranjbar R. Evaluation of *Helicobacter pylori* infection in patients with common migraine headache. *Arch Med Sci*. 2011;7(5):844–9.
 31. Faraji F, Zarinfar N, Zanjani AT, Morteza A. The effect of *Helicobacter pylori* eradication on migraine: a randomized, double blind, controlled trial. *Pain Physician*. 2012; 15(6): 495-8.